Publication: Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: Insights from the GARFIELD-AF registry
Issued Date
2018-02-07
Resource Type
ISSN
15229645
0195668X
0195668X
Other identifier(s)
2-s2.0-85042516795
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Heart Journal. Vol.39, No.6 (2018), 464-473
Suggested Citation
Freek W.A. Verheugt, Haiyan Gao, Wael Al Mahmeed, Giuseppe Ambrosio, Pantep Angchaisuksiri, Dan Atar, Jean Pierre Bassand, A. John Camm, Frank Cools, John Eikelboom, Gloria Kayani, Toon Wei Lim, Frank Misselwitz, Karen S. Pieper, Martin Van Eickels, Ajay K. Kakkar Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: Insights from the GARFIELD-AF registry. European Heart Journal. Vol.39, No.6 (2018), 464-473. doi:10.1093/eurheartj/ehx730 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46951
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: Insights from the GARFIELD-AF registry
Other Contributor(s)
National University Health System
Bayer Pharma AG
Population Health Research Institute, Ontario
Ulleval University Hospital
Universite de Franche-Comte
Duke Clinical Research Institute
St George's University of London
Algemeen Ziekenhuis Klina
Our Lady Hospital - Amsterdam
UCL
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Thrombosis Research Institute
Bayer AG
Università degli Studi di Perugia
Bayer Pharma AG
Population Health Research Institute, Ontario
Ulleval University Hospital
Universite de Franche-Comte
Duke Clinical Research Institute
St George's University of London
Algemeen Ziekenhuis Klina
Our Lady Hospital - Amsterdam
UCL
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Thrombosis Research Institute
Bayer AG
Università degli Studi di Perugia
Abstract
© The Author 2017. Aims Current atrial fibrillation (AF) guidelines discourage antiplatelet (AP) monotherapy as alternative to anticoagulants (ACs). Why AP only is still used is largely unknown. Methods and results Factors associated with AP monotherapy prescription were analysed in GARFIELD-AF, a registry of patients with newly diagnosed (6 weeks) AF and 1 investigator-determined stroke risk factor. We analysed 51 270 patients from 35 countries enrolled into five sequential cohorts between 2010 and 2016. Overall, 20.7% of patients received AP monotherapy, 52.1% AC monotherapy, and 14.1% AP AC. Most AP monotherapy (82.5%) and AC monotherapy (86.8%) patients were CHA2DS2-VASc 2. Compared with patients on AC monotherapy, AP monotherapy patients were frequently Chinese (vs. Caucasian, odds ratio 2.73) and more likely to have persistent AF (1.32), history of coronary artery disease (2.41) or other vascular disease (1.67), bleeding (2.11), or dementia (1.81). The odds for AP monotherapy increased with 5 years of age increments for patients 75 years (1.24) but decreased with age increments for patients 55-75 years (0.86). Antiplatelet monotherapy patients were less likely to have paroxysmal (0.67) or permanent AF (0.57), history of embolism (0.56), or alcohol use (0.90). With each cohort, AP monotherapy declined (P 0.0001), especially non-indicated use. AP AC and no antithrombotic therapy were unchanged. However, even in 2015 and 2016, about 50% of AP-Treated patients had no indication except AF (71% were CHA2DS2-VASc 2). Conclusion Prescribing AP monotherapy in newly diagnosed AF has declined, but even nowadays a substantial proportion of AP-Treated patients with AF have no indication for AP. All rights reserved.